Inicio・Lista de Acciones・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Cerrado

SectorSanidad

5.89 -1.17

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.73

Máximo

Métricas clave
By Trading Economics
Ingresos	-187M -180M
Ventas	78M 234M
P/B Media del Sector	8.634 57.366
BPA	0.6
Margen de beneficios	-76.91
Empleados	900
EBITDA	-205M -156M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+67.5% upside

Dividendos
By Acuity
Próximas Ganancias	28 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-112M 266M
Apertura anterior	7.06
Cierre anterior	5.89

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

46 / 340 Clasificación en Healthcare

Emergent BioSolutions Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ago 2026, 20:07 UTC

News

Emergent BioSolutions Inc. is under investigation, following a $180.2 million net loss and reduced revenue guidance, contributing to a decline in shares today.

26 ago 2026, 20:08 UTC

Emergent BioSolutions Inc shares are higher, reflecting strong upward momentum since Tuesday. The stock remains well above its 20-day moving average.

25 ago 2026, 20:07 UTC

Emergent BioSolutions Inc shares are higher during Tuesday's session, continuing a strong advance since Monday's close amid easing Treasury yields and lower oil prices.

24 ago 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a cumulative increase since Friday. The stock remains below its 20-day moving average.

21 ago 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a steady upward trend since Thursday's close. No specific news was identified to explain the movement.

20 ago 2026, 19:02 UTC

News

Emergent BioSolutions Inc faces scrutiny after a $191.3 million impairment charge and a reduced revenue outlook, contributing to a decline in shares.

19 ago 2026, 19:52 UTC

Emergent BioSolutions Inc is trading higher during Wednesday's session, recovering from earlier lows and reflecting strength since Tuesday's close. No specific news was identified.

18 ago 2026, 20:06 UTC

Emergent BioSolutions Inc shares are higher today, reflecting a broader market recovery. The stock remains below its 20-day moving average and prior month levels.

17 ago 2026, 19:56 UTC

News

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

13 ago 2026, 19:51 UTC

Macro Event

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

12 ago 2026, 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

11 ago 2026, 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

10 ago 2026, 19:51 UTC

News

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

7 ago 2026, 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

6 ago 2026, 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

5 ago 2026, 22:51 UTC

News

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

29 jul 2026, 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

27 jul 2026, 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

23 jul 2026, 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.

Comparación entre iguales

Cambio de precio

Emergent BioSolutions Inc previsión

Precio Objetivo

By TipRanks

67.5% repunte

Estimación a 12 Meses

Media 10 USD 67.5%

Máximo 10 USD

Mínimo 10 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Emergent BioSolutions Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Emergent BioSolutions Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

46 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.